Pfizer is deploying a cumulative ~$10 billion savings program across SG&A and manufacturing to compress its cost base before peak LOE pressure in 2027-2030. Success would stabilize adjusted margins even as legacy products face generic erosion, converting a patent-cliff story into an efficiency story.
the thesis · admitted · the reason above is the thesis, not printed twice
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedfour sentences · whole, uncut
the claims it rests on · in our words, not the filing’s